Transforming Health

with Cutting-

Edge

Biopharma

Solutions

Our products are being developed for and are intended to treat complex diseases and unmet medical needs including Ischemia and Hypoxia Within Stroke, Sickle Cell Disease, and Cystic Fibrosis

discover our product

Prolong
Pharmaceuticals

Prolong Pharmaceuticals

Meeting critical
unmet medical needs.

We are a clinical-stage biopharma leader developing innovative treatments for CNS, Hematology, and Respiratory Disorders.

about us

Our Team

Innovative Leaders in Biotech

Our leadership team has driven success in multiple pharmaceutical and biotechnology companies. Prolong’s founders invented PEGylation, a breakthrough drug delivery technology responsible for many life-improving drugs for hepatitis, kidney disease, and other severe conditions.

meet the team

PP-007 Sanguinate®

Pipeline

PEGfinity Innovative Development

Our PEGylated candidates include a multifunctional gas transfer agent. The PEGfinity process rapidly generates leads and fine-tunes protein function and stability.

How it works

Multi-Modal Therapy

PP-007 (Sanguinate®) restores homeostasis by delivering oxygen to hypoxic tissue and carbon monoxide for improved perfusion and reduced inflammation.

Clinical trials

Proven PEGylation Technology

PEGylation technology, seen in FDA-approved drugs like Neulasta and Krystexxa, is proven. Prolong applies this technology in novel ways to meet critical medical needs.